Slingshot members are tracking this event:

Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis' Cosentyx (secukinumab) in ankylosing spondylitis (AS) were published

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 23, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Measure, Phase Iii, Cosentyx, Secukinumab, Phase 1, Ankylosing Spondylitis